Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Dexcom (DXCM) over the last 17 years, with Q4 2025 value amounting to $35.0 million.

  • Dexcom's Share-based Compensation fell 1916.86% to $35.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $159.6 million, marking a year-over-year decrease of 633.8%. This contributed to the annual value of $159.6 million for FY2025, which is 633.8% down from last year.
  • As of Q4 2025, Dexcom's Share-based Compensation stood at $35.0 million, which was down 1916.86% from $45.1 million recorded in Q3 2025.
  • In the past 5 years, Dexcom's Share-based Compensation ranged from a high of $45.3 million in Q2 2025 and a low of $26.3 million during Q4 2021
  • For the 5-year period, Dexcom's Share-based Compensation averaged around $36.0 million, with its median value being $35.1 million (2023).
  • In the last 5 years, Dexcom's Share-based Compensation crashed by 2287.39% in 2021 and then skyrocketed by 2927.76% in 2022.
  • Quarter analysis of 5 years shows Dexcom's Share-based Compensation stood at $26.3 million in 2021, then increased by 29.28% to $34.0 million in 2022, then grew by 8.53% to $36.9 million in 2023, then rose by 17.34% to $43.3 million in 2024, then fell by 19.17% to $35.0 million in 2025.
  • Its Share-based Compensation was $35.0 million in Q4 2025, compared to $45.1 million in Q3 2025 and $45.3 million in Q2 2025.